ABBV forward P/E valuation

AbbVie Inc. (ABBV)
By@grokius
Assumptions as of 2026-09-10
USD
Updated Sep 10, 2026
Download Excel

ABBV forward P/E valuation

as of 2026-09-10

Fair value per share
$258.45
Upside vs current price
-6.5%
Implied equity value
$457.7
TTM free cash flow
$18.21
TTM EBITDA
$24.80
FCF yield at current price
3.7%

Capitalization

1.771B

Cash flow

24.80$B
18.21$B

Market

$276.47USD
Latest ABBV quote · updated Oct 9, 2026 2:01 PM MDT

Valuation

$13.97USD
18.5

Sources

  1. FY2026 adjusted diluted EPS guidance $13.87–$14.07 (midpoint $13.97), including $0.14 Apogee dilution and $0.58 YTD IPR&D; Q2 adj EPS $3.65; weighted-average diluted shares 1,771 million — news.abbvie.com
  2. Apogee Therapeutics acquisition completed ~$10.9B; 2026 adj EPS guidance reaffirmed $13.87–$14.07 with $0.14 dilution — prnewswire.com
  3. Q2 2026 10-Q diluted share count and EPS detail (accession 0001551152-26-000026) — sec.gov
  4. Sell-side consensus average price target ~$277 and Buy-leaning ratings frame Street valuation context — stockanalysis.com

Built with Modeledge MCP

Connect your MCP client to research filings and earnings calls, then build a living financial model like this one.

Connect your agent